Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

Diamyd Medical

9.37 SEK

-2.60 %

Less than 1K followers

DMYD B

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
-2.60 %
-8.32 %
-21.66 %
-4.00 %
-42.74 %
-37.41 %
-38.59 %
-68.80 %
+212.05 %

Diamyd Medical is active in diabetes research. The company has developed a vaccine that contains the active ingredient and molecule GAD, a substance that has the potential to be an important part of the prevention of diabetes treatments in the future. The company has operations on a global level with the largest presence in the Nordic region. The headquarters are located in Stockholm.

Read more
Market cap
1.29B SEK
Turnover
2.57M SEK
Revenue
130K
EBIT %
-140,953.85 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
28.1
2026

Interim report Q1'26

25.3
2026

Interim report Q2'26

24.6
2026

Interim report Q3'26

All
Press releases
ShowingAll content types
Regulatory press release12/4/2025, 4:00 PM

Bulletin from Annual General Meeting of Diamyd Medical AB

Diamyd Medical
Regulatory press release12/2/2025, 9:55 AM

Diamyd Medical AB: Annual Report 2024/2025

Diamyd Medical
Press release12/1/2025, 6:41 AM

BioStock: Lif's sustainability conference 2025 with a focus on transition, competitiveness and sustainable production

Diamyd Medical

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release11/14/2025, 7:45 AM

Diamyd Medical AB: Diamyd Medical's pivotal Phase 3 Type 1 Diabetes trial clears last safety review ahead of early readout in March 2026

Diamyd Medical
Regulatory press release11/13/2025, 7:28 AM

Diamyd Medical AB: Information about the Annual Report 2024/2025

Diamyd Medical
Regulatory press release11/12/2025, 11:45 AM

Diamyd Medical AB: Diamyd Medical marks World Diabetes Day with expert panel on the future of Type 1 Diabetes treatment

Diamyd Medical
Press release10/10/2025, 10:16 AM

BioStock: Screening - a potential game changer for type 1 diabetes

Diamyd Medical
Press release10/9/2025, 5:27 AM

DNB Carnegie Access: Diamyd Medical: Solid finish to the fiscal year

Diamyd Medical
Regulatory press release10/8/2025, 6:15 AM

Diamyd Medical AB: Year-End Report 24/25

Diamyd Medical
Regulatory press release10/3/2025, 12:40 PM

Diamyd Medical AB: Hong Kong grants precision medicine patent to Diamyd Medical for insulin antigen treatment in type 1 diabetes

Diamyd Medical
Press release9/25/2025, 9:36 AM

BioStock: Video from Diamyd Medical's presentation at BioStock Investing in Life Science – From Seed to Success

Diamyd Medical
Regulatory press release9/11/2025, 8:00 AM

Diamyd Medical AB: New analysis to be presented at EASD supports potential of Diamyd[®] to delay the progression of Stage 3 Type 1 Diabetes

Diamyd Medical
Regulatory press release9/10/2025, 7:00 AM

Diamyd Medical AB: Eurasia to grant precision medicine patent to Diamyd Medical for insulin antigen treatment in type 1 diabetes

Diamyd Medical
Regulatory press release9/5/2025, 11:00 AM

Diamyd Medical AB: ASSET partnership, coordinated by Diamyd Medical, organizes 2[nd] annual Type 1 Diabetes screening conference

Diamyd Medical
Press release9/3/2025, 4:18 AM

DNB Carnegie Access: Diamyd Medical: DNB Carnegie’s Micro & Small Cap Day 2025 – highlights

Diamyd Medical
Regulatory press release7/22/2025, 2:00 PM

Diamyd Medical AB: Diamyd Medical releases the full video recording from a panel discussion at the ADA meeting in June

Diamyd Medical
Press release7/1/2025, 9:44 AM

DNB Carnegie Access: Diamyd Medical: Progress towards key catalyst in March 2026 – Q3 review

Diamyd Medical
Press release7/1/2025, 8:00 AM

DNB Carnegie Access: Diamyd Medical: Intervju - Närmar sig viktiga studiedata

Diamyd Medical
Regulatory press release6/25/2025, 6:15 AM

Diamyd Medical AB: Quarterly Report 3 24/25

Diamyd Medical
Regulatory press release6/16/2025, 1:05 PM

Diamyd Medical AB: Diamyd Medical to participate in two key US diabetes events

Diamyd Medical
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.